August 29, 2018 / 5:24 AM / 22 days ago

BRIEF-Novartis melanoma cocktail gets additional EU approval

Aug 29 (Reuters) - Novartis AG:

* EUROPEAN COMMISSION APPROVES NOVARTIS COMBINATION THERAPY TAFINLAR® + MEKINIST® FOR ADJUVANT TREATMENT OF BRAF V600 MUTATION-POSITIVE MELANOMA

* EC APPROVAL MARKS THIRD INDICATION IN EUROPE FOR LEADING BRAF/MEK INHIBITOR COMBINATION TAFINLAR + MEKINIST Source text for Eikon: Further company coverage: (Reporting By Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below